Co Diovan

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Co Diovan

Quick Facts

Property Description
Active ingredients Valsartan and Hydrochlorothiazide
Form Film-coated tablet (Oral preparation)
Pharmacological class Combination antihypertensive agent
General purpose Sustained management of high blood pressure
Origin Synthetic pharmaceutical

Combination Therapy: What Type of Medicine is Co Diovan?

Co Diovan is a widely recognized prescription-only fixed-dose combination (FDC) categorized as a combination antihypertensive agent. This synthetic pharmaceutical is an oral preparation, administered as a film-coated tablet, utilized for the management of essential hypertension. The medicine’s FDC structure is clinically recognized for supporting patient adherence by consolidating two therapeutic actions into a single tablet. It is commonly used in adult patients whose pressure control requires the complementary effects of more than one agent, thus providing dual-mechanism coverage.

Active Ingredients: Valsartan and Hydrochlorothiazide Composition

The product’s function is defined by its two distinct active ingredients: Valsartan and Hydrochlorothiazide. Valsartan is classified as an Angiotensin II Receptor Blocker (ARB), which modulates the circulatory system's hormonal mechanisms, while Hydrochlorothiazide acts as a Thiazide diuretic, contributing to the reduction of fluid volume. The composition features these two agents in a single oral form, a specific pairing favored in treatment guidelines for patients requiring comprehensive support across both vascular tone and fluid regulation.

General Purpose: What Does This Combination Antihypertensive Achieve?

The general purpose of the Hydrochlorothiazide-Valsartan combination is to secure sustained and effective blood pressure reduction. By implementing a dual strategy of decreasing systemic vascular resistance and promoting controlled volume depletion, the medicine minimizes the persistent strain on the heart and arteries. This foundational circulatory support is critical for long-term cardiovascular risk reduction in individuals managing chronic elevated pressure.

What side effects are possible with Co Diovan?

Possible Side Effects and Safety Information

The safety profile for the fixed-dose combination of valsartan and hydrochlorothiazide is documented based on official regulatory data. Adverse reactions are classified by frequency and grouped into System-Organ Classes.

Frequency-Classified Adverse Reactions

Side effects categorized as very common in official regulatory documents include hypokalemia (low potassium) and increases in blood lipids such as cholesterol and triglycerides. Effects commonly documented include dizziness, headache, and fatigue, alongside metabolic changes like hyponatremia (low sodium) and hyperuricemia (high uric acid). Uncommon reactions may include coughing and joint pain.

Serious Adverse Reactions and Systemic Concerns

Rare but serious adverse reactions documented in regulatory sources include angioedema, a severe hypersensitivity reaction involving swelling of the face, lips, or throat. The safety information also notes the risk of Acute Angle-Closure Glaucoma, a rare ocular event typically appearing within hours to weeks of initiating therapy. Other serious concerns involve the potential for severe, symptomatic hypotension and instances of acute renal failure in specific high-risk patient populations.

Population-Specific Constraints and Restrictions

Official labeling includes strict constraints for certain populations. The medicine is contraindicated in pregnancy due to the risk of fetal injury or death. It is also contraindicated in individuals with anuria (inability to pass urine) and in those with known hypersensitivity to sulfonamide derivatives. Caution is noted for use in patients with pre-existing volume depletion or severe hepatic impairment, as these states can increase the risk of adverse outcomes.

Overdose and Emergency Response

Overdose with Co Diovan (valsartan/hydrochlorothiazide) is officially documented to result from the combined effects of its two components, leading to Profound Circulatory Depression and Severe Fluid and Electrolyte Imbalance. The most prominent clinical sign of overdosage is a state of profound hypotension, which may be accompanied by a compensatory tachycardia or, in some cases, bradycardia. The diuretic component commonly leads to volume depletion and significant electrolyte shifts, including hypokalemia and hyponatremia, as documented in regulatory labeling.

The official documentation specifies that severe overdosage carries the risk of life-threatening conditions such as shock due to prolonged hypotension, or cardiac arrhythmias that may arise from profound electrolyte disturbances. For any suspected overdose, regulatory guidance mandates that the patient seek immediate medical attention or contact a Poison Control Center without delay.

Management is strictly symptomatic and supportive, as no specific antidote is known for the combination product. For symptomatic hypotension, the required emergency action includes placing the patient in the supine position and administering an intravenous infusion of normal saline if necessary. Continuous monitoring of vital signs, serum electrolytes, and renal function is required during clinical observation. Furthermore, Valsartan is highly protein-bound and is not expected to be removed by hemodialysis.

Therapeutic Uses of Co Diovan

Targeting Hypertension Uncontrolled by Single Agents

This combination therapy is generally used for the sustained management of Essential Hypertension (high blood pressure) in adult patients whose pressure measurements remain above target goals despite initial management with a single drug. It is indicated for patients not adequately controlled with monotherapy or as initial therapy in those likely to need multiple drugs to achieve blood pressure goals. The primary purpose is to support the achievement of stable pressure management in these more challenging clinical contexts.

Supporting Long-Term Cardiovascular Health

Effective blood pressure management is commonly used to support long-term cardiovascular health and helps address the persistent strain that elevated pressure places on the circulatory system. By assisting with pressure control over time, the therapy may assist in reducing the burden of systemic strain to support the preservation of major organ function. This dual approach is applied in scenarios where additional management of discomfort or strain is considered appropriate.

Quick Fact: Management for Persistent Systemic Strain

This therapy is primarily used to manage Essential Hypertension and to support long-term cardiovascular health by easing the persistent burden high pressure places on the body. This dual support is designed to provide comprehensive circulatory management and generally contributes to the benefit of sustained management of pressure control.

Eligibility and Restrictions for Use

Eligibility Map: Who can and cannot use Co Diovan — Official Regulatory Information

Eligibility Scope Detail
Populations for whom use is allowed Adults (18 years and older) who require combination therapy for essential hypertension.
Populations for whom use is contraindicated Patients with known allergies to Valsartan, Hydrochlorothiazide, or sulfonamide medicines. Prohibited with other blood pressure medicines containing Aliskiren in patients who have diabetes or certain kidney impairment.
Pregnancy and lactation eligibility status Contraindicated in pregnancy and must be discontinued immediately if pregnancy is detected; use is not recommended during breastfeeding.
Age-related eligibility rules Not recommended for children and adolescents under 18 years of age, as safety and efficacy have not been established in this group.
Condition-specific non-eligibility Prohibited in severe renal impairment (creatinine clearance <30 ml/min) and anuria. Also contraindicated in severe hepatic impairment, biliary cirrhosis, cholestasis, or refractory electrolyte imbalances.
Eligibility-related restrictions Use requires caution in patients with uncorrected salt or volume depletion, or those with unilateral or bilateral renal artery stenosis.

Connection to the Overall Eligibility Profile

Official regulatory documents establish a clear framework of absolute exclusions and restrictions for Co Diovan use. The drug is designated for use only in the adult population and is strictly prohibited in cases involving severe organ dysfunction (liver or kidney), specific metabolic conditions, or pregnancy. These criteria focus on patient status to define who is formally eligible for the medicine, and who is officially excluded from use.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Contraindicated Combinations and Key Restrictions

The official regulatory profile formally classifies co-administration with Aliskiren as contraindicated in patients with Type 2 Diabetes or those with moderate-to-severe renal impairment. Due to its Hydrochlorothiazide component, the medicine is prohibited in patients with anuria or severe renal impairment (creatinine clearance < 30 mL/min). Co-administration with agents that increase potassium levels, such as Potassium-sparing diuretics or Potassium supplements, carries a documented risk of hyperkalemia.

Pharmacodynamic and Exposure-Modifying Interactions

Co-administration with Lithium leads to a documented increase in serum lithium concentrations and toxicity because the medicine reduces Lithium's renal clearance. Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) may reduce the diuretic and antihypertensive effects and increase the risk of renal function deterioration. Other antihypertensive agents, as well as alcohol, narcotics, or barbiturates, may potentiate the effect of orthostatic hypotension.

Absorption and Metabolic Notes

Substances like Cholestyramine or Colestipol may cause reduced absorption of the Hydrochlorothiazide component. The Hydrochlorothiazide component may also require dosage adjustment of antidiabetic drugs due to its potential to alter glucose tolerance. Valsartan has a low extent of metabolism, making CYP P450-mediated drug interactions unlikely.

Mechanism of Action

Modulation of the Renin-Angiotensin System

Valsartan acts as an Angiotensin II Receptor Blocker (ARB) by selectively binding to and blocking the angiotensin II type 1 (AT1) receptors.

Antagonism of the AT1 receptor prevents the signaling consequences mediated by Angiotensin II, a peptide within the RAAS cascade. This action specifically inhibits AT1-mediated vascular smooth muscle contraction, resulting in a reduction of vascular tone.


Regulation of Fluid and Electrolyte Excretion

Hydrochlorothiazide, a thiazide diuretic, engages mechanisms within the kidney's distal convoluted tubules. It specifically inhibits the sodium-chloride cotransporter (NaCl cotransporter). This inhibition reduces the tubular reabsorption of sodium and chloride ions, thereby altering osmotic pressure and increasing the net excretion of water and electrolytes.


Dual-Pathway Mechanistic Convergence

The combined actions of AT1 receptor antagonism and NaCl cotransporter inhibition converge two distinct pharmacodynamic pathways. This promotes a coordinated, dual-mechanism alteration in both systemic vascular tone and circulating fluid volume.

Dosage and Administration Information

The use of Co Diovan (valsartan/hydrochlorothiazide) follows the standard protocols for its oral administration.


Official Administration Guidelines

Administration Scope Procedural Details
Route of administration Oral ingestion only, as a film-coated tablet.
Dosing schedule The usual starting dose is one 160 mg / 12.5 mg tablet once daily. The dosage can be titrated up to a maximum of 320 mg valsartan / 25 mg hydrochlorothiazide once daily.
Timing in relation to meals May be taken with or without food.
Preparation requirements The tablet should be swallowed whole with water. Do not break, crush, or chew.
Age-group rules Pediatric: Not recommended for use in children under 18 years. Older Adults: No initial dose adjustment is typically required.
Missed-dose rules If a dose is missed, take it as soon as possible, but skip the missed dose if it is almost time for the next scheduled dose. Do not take a double dose.

Procedural Structure

Instruction Classification Detail
Administration method type Oral
Frequency pattern Once Daily
Use-context constraints Contraindicated in severe renal impairment (CrCl < 30 mL/min) or severe hepatic impairment/cholestasis. Therapy initiation may require correction of pre-existing volume depletion.

Connection to the overall use protocol: The administration protocol establishes the combination as a once-daily oral treatment with defined starting and maximum doses. Dosage adjustments are permitted only after specific intervals, typically 1 to 4 weeks, to assess control. This structured approach ensures standardized use and highlights key constraints related to patient volume status and organ function.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Co Diovan

Evidence for Use in Essential Hypertension

This section summarizes the types of randomized controlled trials (RCTs) and other studies that have evaluated the combination therapy for conditions where high blood pressure was evaluated. Research has explored the use of this fixed-dose combination (FDC) primarily in adult patients whose high blood pressure was not adequately controlled by taking a single medication alone. A primary part of the evidence comes from short-term, controlled trials that compared the FDC to its individual components or an inactive substance (placebo). These studies were typically randomized and double-blind, used to observe patterns related to blood pressure measurements under specific, controlled conditions.

Measuring the Effect in Clinical Trials

In these trials, research examined outcomes monitoring physiological strain or stress by focusing on changes in systolic and diastolic blood pressure. Studies monitored the change in blood pressure readings from the start of the study over defined time intervals, often up to 8 to 12 weeks. The findings describe patterns observed in the studies where the combination was associated with various measurements of blood pressure change compared to the individual components or placebo. Furthermore, studies reported the number of people who achieved specific blood pressure values that were pre-defined as treatment goals.

Long-Term Evidence and Cardiovascular Outcomes

The core efficacy trials that directly studied this specific FDC were generally short-term, typically lasting only a few months. Therefore, long-term effects are not fully established directly through multi-year controlled trials of the combination itself. The knowledge about the relationship between blood pressure change with this combination and long-term research outcomes associated with major adverse cardiovascular events (such as stroke or heart attack) is largely extrapolated. This scientific rationale relies on the established understanding that sustained blood pressure changes from its individual drug classes were associated with patterns related to long-term outcomes.

Evidence in Specific Patient Groups

This section outlines the types of research available regarding how the combination was studied in defined subgroups, such as older adults or patients with certain underlying risk factors. Research was evaluated in broad populations of hypertensive adults, and subgroup analyses sometimes explored patterns in patients defined by characteristics like race or ethnicity. However, data for certain groups remain insufficient. For instance, there is limited information available for the safety and patterns of response in children and adolescents (under 18 years).

Study Limitations and Unanswered Research Questions

The primary limitation frames include the fact that studies relied on surrogate endpoints (blood pressure) rather than definitive, multi-year outcomes (major cardiovascular events). Research provides context but not individual predictions, and the follow-up durations were limited in the specific FDC efficacy trials. Consequently, certainty remains low regarding the direct long-term findings associated with the fixed combination's use and definitive clinical events.

Frequently Asked Questions (FAQ)

Common questions about Co Diovan (FAQ)


Q: How long does it usually take for Co Diovan to start working?

Studies on the valsartan component show that the blood pressure-lowering process begins approximately 2 hours after taking a single dose. However, the official product information indicates that the maximum reduction in blood pressure is generally achieved after about 4 weeks of consistent daily treatment.


Q: If I miss a dose of Co Diovan, what is the generally recommended action?

According to the official administration rules, the regulatory guidance states that a missed dose may be taken as soon as it is remembered. However, the missed dose should be skipped if it is almost time for the next scheduled dose. It is specifically noted that a double dose should not be taken to compensate for the missed one.


Q: Does Co Diovan interact with common pain relievers like ibuprofen?

Official documentation notes that co-administration with Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), a class that includes ibuprofen, may reduce the expected blood pressure-lowering effect. This combination may also increase the risk of changes in kidney function.


Q: Are there any specific foods or drinks to avoid while taking Co Diovan?

The medicine may be taken with or without food as the timing of meals does not affect its administration. However, regulatory documents warn that alcohol may increase the effect of orthostatic hypotension (dizziness when standing up), which is an important consideration.


Q: Is Co Diovan prescribed for heart failure?

The combination product Co Diovan is officially indicated by the FDA primarily for the treatment of high blood pressure (hypertension). While one of the active ingredients, valsartan, is approved for use in heart failure, the combination product itself is not indicated for that specific condition.


Q: What kind of studies support the use of Co Diovan?

The medicine's use is supported by short-term (4-12 week) randomized, double-blind clinical trials. These studies focused on adult patients whose high blood pressure was not controlled by a single medication. The trials compared the combination product to its individual components or an inactive substance (placebo).


Q: Is Co Diovan used for high blood pressure in children?

Official regulatory documents state that Co Diovan is not recommended for use in children and adolescents under 18 years of age. This is because the safety and effectiveness of the combination medicine have not been established in patients within this age group.


Q: What is the benefit of taking a combination pill like Co Diovan?

The combination is typically prescribed for patients whose blood pressure has not been adequately controlled by a single drug. Clinical studies indicate that the combination of the two ingredients is associated with greater reductions in blood pressure compared to either ingredient used alone at corresponding doses, providing a dual approach to management.


Q: Do cold and flu medicines interact with Co Diovan?

The official product label does not name the broad category of 'cold and flu medicines.' However, many common over-the-counter cold and flu products may contain ingredients that are documented to interact, such as NSAIDs, or agents like alcohol which may affect blood pressure or increase the risk of dizziness.


Q: Is a persistent dry cough a possible side effect of Co Diovan?

Official safety data lists coughing as an uncommon side effect of the medicine. This is a common concern with blood pressure medicines, but the label for the valsartan component does not typically specify a 'dry' cough, which is often associated with a different class of medicine.


Q: Is it common for doctors to switch from a single drug to Co Diovan?

Yes, regulatory documents indicate that Co Diovan is specifically intended for use in patients whose blood pressure is not adequately controlled on monotherapy (treatment with only one drug). This use case establishes switching to the combination as a standard treatment protocol.


Q: Does Co Diovan work to lower blood pressure immediately?

The onset of the antihypertensive effect begins within approximately 2 hours after taking the medicine. However, the full, maximal effect is not immediate; the maximum blood pressure reduction is not typically achieved until about 4 weeks of consistent daily use.


Q: Is it okay to take Co Diovan in the morning or evening?

The official labeling states that the medicine is a once-daily oral treatment that can be taken with or without food. While the specific time of day is not strictly mandated, other combination products containing the diuretic component are sometimes suggested to be taken preferably in the morning.


Q: Is it normal to feel a bit dizzy when first starting Co Diovan?

Dizziness is documented as a common adverse reaction in the safety profile. The label also specifically notes that lightheadedness or fainting may occur, especially when getting up suddenly. These effects are often associated with the initial phase of adjustment to blood pressure medication.


Q: Can Co Diovan cause kidney problems?

Regulatory documents indicate that impaired renal function and even acute renal failure have been documented in postmarketing experience. The medicine can cause changes in kidney function, particularly in susceptible patients with pre-existing kidney issues or severe heart failure.


Q: Are there any known severe side effects of Co Diovan that I should be aware of?

The most serious warnings relate to the risk of fetal injury or death if the medicine is taken during pregnancy. Other rare but severe reactions documented in the official safety information include angioedema (severe swelling) and the potential for dangerously low blood pressure (symptomatic hypotension).


Q: Can I take Co Diovan if I am taking supplements like potassium or calcium?

Official labeling advises caution regarding supplements that affect electrolytes. Specifically, taking potassium supplements or potassium-sparing diuretics carries a documented risk of hyperkalemia (high potassium levels). Discussions about all supplements, including potassium, are part of the medical protocol.


Q: How do the two drugs in Co Diovan work together?

The two active ingredients, valsartan and hydrochlorothiazide, work through two separate mechanisms. Valsartan blocks a hormone (angiotensin II) that constricts blood vessels, while hydrochlorothiazide is a diuretic that helps the kidneys remove salt and excess water. This dual approach provides a comprehensive strategy for lowering blood pressure.


Q: Is Co Diovan known to cause issues with blood sugar levels?

The hydrochlorothiazide component may alter glucose tolerance, which refers to how the body processes sugar. Because of this potential effect, official documents indicate that a dosage adjustment of antidiabetic drugs may be required for patients taking both medications.


Q: Does Co Diovan have known interactions with alcohol?

Yes, official labeling notes that consuming alcohol may intensify the effect of orthostatic hypotension due to the hydrochlorothiazide component. Orthostatic hypotension is the sudden drop in blood pressure that can cause dizziness or fainting when standing up.


Q: Is there a link between Co Diovan and skin rash?

Regulatory documents list rash as an adverse reaction documented in the postmarketing experience of valsartan. Additionally, the hydrochlorothiazide component is a sulfonamide derivative, and hypersensitivity reactions to these drugs can include skin manifestations.


Q: Do clinical trials show a reduction in cardiovascular events with Co Diovan?

The main efficacy trials for this specific combination were generally short-term and focused on measuring blood pressure reduction. Long-term research concerning major cardiovascular events (like heart attack or stroke) with the combination is largely extrapolated from extensive studies on the individual drug classes to which the ingredients belong.


Q: What kind of tests are usually done before prescribing Co Diovan?

The official protocol requires assessment of certain health constraints. Since the drug is contraindicated in severe kidney impairment, assessment of creatinine clearance (a measure of kidney function) is part of the required protocol. Similarly, pre-existing volume depletion or low salt status may require correction before therapy can begin.


Q: Are people who take Co Diovan monitored for specific laboratory changes?

Yes, official documents advise that healthcare providers should monitor certain laboratory values in susceptible patients. This typically includes monitoring renal function and potassium levels. Additionally, patients taking the drug lithium must have their serum concentrations monitored closely.


Q: Does Co Diovan treat symptoms or the underlying cause of high blood pressure?

Co Diovan is indicated for the sustained management of high blood pressure. The medicine works to directly lower blood pressure, which, according to the label, reduces the risk of fatal and nonfatal cardiovascular events over time. It is a long-term treatment strategy for chronic elevated pressure.

How should Co Diovan be stored and disposed of?

How to Store and Dispose of Co Diovan?

The storage and disposal of Co Diovan tablets must adhere strictly to the conditions mandated by regulatory labeling to maintain product stability and protect public safety.


Official Storage Requirements

Condition Requirement
Temperature Store at Controlled Room Temperature, typically 25^circC (77^circF), with excursions permitted from 15^circC to 30^circC.
Protection Mandatory protection from moisture and freezing. Keep away from heat and direct light.
Packaging Keep the tablets in their tightly closed container or original packaging.
Child Safety Keep out of the sight and reach of children at all times.

Disposal Protocol

Disposal of unused or expired medicine should not be done through household trash or wastewater. To ensure environmental protection, consult a healthcare professional, pharmacist, or local waste disposal service for instructions on how to properly discard the outdated or unwanted product.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Co Diovan found in:

A-Z Index: